Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Publication bias in pharmacogenetics of adverse reaction to antiseizure drugs: An umbrella review and a meta-epidemiological study.

Tytuł:
Publication bias in pharmacogenetics of adverse reaction to antiseizure drugs: An umbrella review and a meta-epidemiological study.
Autorzy:
Bally S; Laboratoire de Biométrie et Biologie Evolutive UMR5558, Université Lyon 1, CNRS, Villeurbanne, France.
Cottin J; Service Hospitalo-Universitaire de Pharmacotoxicologie, Pôle de Santé Publique, Hospices Civils de Lyon, Lyon, France.
Gagnieu MC; Laboratoire de Pharmacologie, Groupement Hospitalier Sud, Hospices Civils De Lyon, Lyon, France.
Lega JC; Laboratoire de Biométrie et Biologie Evolutive UMR5558, Université Lyon 1, CNRS, Villeurbanne, France.; Service de Médecine Interne et Vasculaire, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France.
Verstuyft C; CESP, MOODS Team, INSERM, Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre, France.; Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie de Bicêtre, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre, France.
Rheims S; Department of Functional Neurology and Epileptology, Hospices Civils de Lyon, Lyon 1 University, Lyon, France.
Lesca G; Service de Génétique, Groupement Hospitalier Est, Hospices Civils De Lyon, Université Lyon 1, Lyon, France.
Cucherat M; Laboratoire de Biométrie et Biologie Evolutive UMR5558, Université Lyon 1, CNRS, Villeurbanne, France.; Service Hospitalo-Universitaire de Pharmacotoxicologie, Pôle de Santé Publique, Hospices Civils de Lyon, Lyon, France.
Grenet G; Service Hospitalo-Universitaire de Pharmacotoxicologie, Pôle de Santé Publique, Hospices Civils de Lyon, Lyon, France.
Źródło:
PloS one [PLoS One] 2022 Dec 30; Vol. 17 (12), pp. e0278839. Date of Electronic Publication: 2022 Dec 30 (Print Publication: 2022).
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: San Francisco, CA : Public Library of Science
MeSH Terms:
Pharmacogenetics*
Stevens-Johnson Syndrome*
Humans ; Publication Bias ; Systematic Reviews as Topic ; HLA-B Antigens ; Epidemiologic Studies
References:
BMC Med Res Methodol. 2009 Nov 26;9:79. (PMID: 19941636)
Int J Dermatol. 2015 Apr;54(4):488-93. (PMID: 25428396)
Cochrane Database Syst Rev. 2019 Jul 09;7:CD005612. (PMID: 31287157)
Stat Med. 2001 Feb 28;20(4):641-54. (PMID: 11223905)
Drug Res (Stuttg). 2015 Feb;65(2):107-11. (PMID: 24871931)
BMJ. 1997 Sep 13;315(7109):629-34. (PMID: 9310563)
J Dermatol. 2011 Mar;38(3):246-54. (PMID: 21342226)
Pharmacogenet Genomics. 2014 Feb;24(2):94-112. (PMID: 24336023)
JAMA Dermatol. 2013 Sep;149(9):1025-32. (PMID: 23884208)
PLoS Med. 2020 Sep 21;17(9):e1003344. (PMID: 32956352)
Lancet. 2000 Oct 7;356(9237):1228-31. (PMID: 11072941)
Expert Opin Drug Saf. 2019 Mar;18(3):163-172. (PMID: 30704306)
Evid Based Ment Health. 2019 Nov;22(4):153-160. (PMID: 31563865)
BMC Med Res Methodol. 2014 May 23;14:70. (PMID: 24884381)
J Clin Epidemiol. 2000 Feb;53(2):207-16. (PMID: 10729693)
Medicine (Baltimore). 2019 Jun;98(23):e15987. (PMID: 31169736)
Biometrics. 1994 Dec;50(4):1088-101. (PMID: 7786990)
BMJ. 2000 Jun 10;320(7249):1574-7. (PMID: 10845965)
J Clin Pharm Ther. 2018 Jun;43(3):408-413. (PMID: 29274302)
Epilepsy Res. 2017 Sep;135:19-28. (PMID: 28618376)
Clin Pharmacol Ther. 2021 Feb;109(2):302-309. (PMID: 32779747)
Anesth Analg. 2016 Oct;123(4):1018-25. (PMID: 27537925)
Biometrics. 2000 Jun;56(2):455-63. (PMID: 10877304)
Clin Pharmacol Ther. 2012 Dec;92(6):757-65. (PMID: 23132554)
Clin Pharmacol Ther. 2018 Apr;103(4):574-581. (PMID: 29392710)
J Dermatol Sci. 2016 May;82(2):69-74. (PMID: 26925817)
Evid Based Med. 2017 Aug;22(4):139-142. (PMID: 28701372)
Seizure. 2018 Aug;60:163-171. (PMID: 30015149)
Pharmacogenomics. 2014 Apr;15(6):857-68. (PMID: 24897291)
BMJ. 2009 Jul 21;339:b2535. (PMID: 19622551)
PLoS Med. 2005 Dec;2(12):e334. (PMID: 16285839)
Rev Neurol (Paris). 2018 May;174(5):278-291. (PMID: 29685430)
Cochrane Database Syst Rev. 2019 Oct 23;10:CD001417. (PMID: 31642054)
BMJ Evid Based Med. 2018 Jun;23(3):84-86. (PMID: 29650725)
BMJ. 2011 Jul 22;343:d4002. (PMID: 21784880)
Substance Nomenclature:
0 (HLA-B Antigens)
Entry Date(s):
Date Created: 20221230 Date Completed: 20230103 Latest Revision: 20230112
Update Code:
20240105
PubMed Central ID:
PMC9803138
DOI:
10.1371/journal.pone.0278839
PMID:
36584134
Czasopismo naukowe
Publication bias may lead to a misestimation in the association between pharmacogenetic biomarkers (PGx) and antiseizure drug's adverse effects (AEs). We aimed to assess its prevalence in this field. We searched for systematic reviews assessing PGx of antiseizure drug's AEs. For each unique association between a PGx, a drug and its AE, we used the available odds ratio (ORs) to generate corresponding funnel plots. We estimated the prevalence of publication bias using visual inspections and asymmetry tests. We explored the impact of publication bias using ORs adjusted for potential publication bias. Twenty-two associations were available. Our visual analysis suggested a publication bias in five out twenty-two funnel plots (23% [95%CI: 8; 45]). The Egger's test showed a significant publication bias in one (HLA-B*15:02 and phenytoin-induced Stevens-Johnson syndrome or toxic epidermal necrolysis, p = 0.03) out of nine (11% [95%CI: 0; 48]) and the Begg's test in one (HLA-B*15:02 and carbamazepine-induced serious cutaneous reactions, p = 0.02) out of ten (10% [95%CI: 0; 45]) assessable funnel plots. Adjusting for publication bias may reduce by half the ORs of the pharmacogenetics associations. Publication bias in the pharmacogenetic of antiseizure drug's AEs is not uncommon and may affect the estimation of the effect of such biomarkers. When conducting pharmacogenetic studies, it is critical to publish also the negative one.
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: SB, JC, MGC, GG declare that they have no competing interest. JCL has received speaker fees and honoraria from Roche. CV has received consulting fees from Genzyme, Novartis and speaker honoraria from Galapagos. SR received speaker and/or consulting fees from UCB Pharma, EISAI, GW Pharma, Idorsia, LivaNova, and Arvelle Therapeutics. GL has received speaker honoraria from GWpharma, Eisai and Biomarin. MC has received consulting fees from Boehringer Ingelheim, SANOFI, AstraZeneca, EISAI and speaker honoraria from SANOFI. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
(Copyright: © 2022 Bally et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies